Wim V.
- Country
- Belgium
- Department
- Gastroenterology - Hepatology
Research Overview
- N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD
- Evaluation of Ethnicity's Impact on Viral Outcomes Post-Cessation of Tenofovir Alafenamide and Entecavir in HBeAg-Negative Chronic Hepatitis B Patients
Data & Insights
Has run more than one trial at 9 of 125 partner sites.
Specializations
Hepatology Focus
This investigator specializes in the study of chronic hepatitis B infection, with particular emphasis on understanding treatment interventions and viral response patterns.
- Viral Hepatitis Management
- Antiviral Therapy Assessment
- Treatment Discontinuation Strategies
The research explores the complexities of nucleos(t)ide analogue treatment in hepatitis B patients.
Ethnic Considerations
The investigator focuses on understanding how ethnicity-specific factors influence treatment outcomes in chronic viral hepatitis.
- Population-specific Response Patterns
- Ethnic Variation Studies
- Personalized Treatment Approaches
Their work examines the relationship between ethnic background and viral response in hepatitis treatment.
Treatment Optimization
The investigator studies controlled treatment interruption strategies in chronic hepatitis B management.
- Treatment Cessation Protocols
- Viral Response Monitoring
- Long-term Outcome Assessment
Their research aims to optimize therapeutic approaches for HBeAg-negative patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.